August 2025RiverVest Mourns Passing of Ronald T. Borchardt, PhD,RiverVest Scientific Advisory Board Member Ronald T. Borchardt, PhDFebruary 18, 1944 - July 15, 2025In MemoriamWith great sadness, RiverVest mourns the passing of Dr. Ronald T. Borchardt, a valued member of our scientific advisory board since 2015. Ron’s...
Glycosylation is crucial to the development of healthy organs and tissues. Could replacing a missing sugar help patients with a rare glycosylation disorder improve coordination and mobility? ...
Learn how Alleviant's no-implant approach addresses the full spectrum of chronic heart failure....
RiverVest Year in Review: 2024...
ST. LOUIS (December 12, 2024)—RiverVest Venture Partners, a leading life science venture capital firm, today announced that John C. Cambier, Ph.D., and Gary De Crescenzo have joined the firm’s Scientific Advisory Board. Composed of leaders in medical research, RiverVest’s Scientific Advisory Board provides expert guidance...
RiverVest speaks with Lyn Baranowski, CEO of portfolio company Avalyn Pharma, about who she is, what brought her to Avalyn, and what fuels her passion for building great companies....
OCTOBER 2024RiverVest Venture Partners Welcomes Nafise Masoumi as Senior Associate Nafise Masoumi, PhDST. LOUIS--(October 16, 2024)--Life sciences venture capital firm RiverVest Venture Partners today announced that Nafise Masoumi, Ph.D. has joined the firm as senior associate based in the San Diego office, where she will focus...
RiverVest speaks with Lyn Baranowski, CEO of portfolio company Avalyn Pharma, about who she is, what brought her to Avalyn, and what fuels her passion for building great companies....
JULY 2024RiverVest Venture Partners Announces Promotions ST. LOUIS (July 18, 2024)ST. LOUIS, July 18, 2024– RiverVest Venture Partners today announced the promotions of two members of its team. Andrew Kleiboeker has been promoted to associate, and Jeff Seitz to senior analyst. "Both Andrew and Jeff have shown...
June 2024O'Donnell Honored for Entrepreneurial Achievement by UC San Diego's Rady School of Management Niall O'Donnell, Ph.D. RiverVest Managing Director San Diego, CA (June 5, 2024) – UC San Diego’s Rady School of Management named Niall O’Donnell, Ph.D. (Rady MBA Class of 2006) the Sullivan Center for...
RiverVest's latest Expert Insight explores the role of patient advocacy groups in therapeutic drug development for patients with rare diseases such as mitochondrial disease. ...
DECEMBER 2023RiverVest Venture Partners Promotes Karen Spilizewski and Isaac Zike to Managing Director and Pascal Krotee to Principal ST. LOUIS (December 14, 2023)ST. LOUIS, December 14, 2023 – RiverVest Venture Partners today announced the promotions of three current team members: Karen Spilizewski and Isaac Zike, Ph.D....
November 2023RiverVest's Pascal Krotee Wins Life Science Catalyst Award Pascal Krotee, Ph.D. RiverVest Senior Associate San Diego, CA (November 1, 2023) – Biocom California today announced the winners of its Eighth Annual Life Science Catalyst Award. RiverVest Senior Associate Pascal Krotee, Ph.D. was among 10 life science...
RiverVest's latest Expert Insight explores the role of patient advocacy groups in therapeutic drug development for patients with rare diseases such as mitochondrial disease. ...
This is a case study of RiverVest portfolio company Good Therapeutics, which was acquired by Roche in 2022 for $250 million upfront plus potential milestone returns....
In this article, Managing Director Niall O’Donnell, Ph.D. discusses the law that transformed orphan drug development and how one actor’s starring role in its passage spurred 40 years of prolific, life-saving innovation. ...